COGT Cogent Biosciences, Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
12:09
May 28
May 28
COGT has received FDA priority review designation with a PDUFA date of November 30, 2026 — a specific regulatory catalyst with defined timing.
LOW
18:19
May 19
May 19
Author adds to ABVX and NKTR positions ahead of key data, expressing bullish conviction on ABVX's high probability of meeting endpoints while holding other biotech names for later review.
HIGH
17:44
May 07
May 07
Long COGT based on speaker's analysis within the broader biotech bull market.
HIGH
11:10
May 03
May 03
Buy COGT for Bezuclastinib's derisked pipeline with imminent NDA decisions in 2L GIST and SM, strong clinical data, >$3B peak sales potential, and strategic M&A appeal as a tuck-in for large pharma.
HIGH
08:54
Apr 30
Apr 30
The author sold all ANL and now holds only NKTR, ABVX, and COGT, signaling a concentrated bullish bet on these biotech names ahead of summer catalysts.
10:59
Apr 24
Apr 24
Buy COGT as it is the sole player in the GIST space, with a year-end price target of $70.
MED
19:24
Apr 07
Apr 07
Initiating a long position in COGT, with a deeper fundamental dive expected to follow.
HIGH
About COGT Analyst Coverage
Buzzberg tracks COGT (Cogent Biosciences, Inc.) across 1 sources. 5 bullish vs 0 bearish calls from 1 analysts. Sentiment: predominantly bullish (71%). 7 total trade ideas tracked.